OUTLOOK AND PLANS INOVIQ remains focused on its vision to be a leading biotechnology company pioneering next-generation diagnostics and therapeutics to enhance patient outcomes in cancer and other diseases. The Company’s priorities over the next 12-months are to expand its EXO-NET exosome isolation tools, partner its lead SubB2M diagnostics, accelerate development of its exosome diagnostics and therapeutics pipeline, and grow revenues from EXO-NET product sales and partnering. The Company expects to report data readouts across its SubB2M tests, exosome diagnostic and therapeutic programs, as well as commercial progress for its EXO-NET research tools and partnering activities over the next 12 months. INOVIQ is strongly positioned with disruptive technology, a multi-product pipeline, commercial partners validating its technology, and an experienced leadership team to execute on strategy, deliver key milestones and grow shareholder value over the next 12 months. INOVIQ thanks shareholders for their ongoing support and looks forward to keeping you informed on our progress. 15 Annual Report 2024 Review of Operations CY 2024 CY 2025 • EXO-NET Supply & Distribution Agreement with Promega • Exosome diagnostic agreement • NEURO-NET validation data • EXO-OC test biomarker validation data • Exosome therapeutic in vitro data • SubB2M breast cancer monitoring study data • Laboratory partner for SubB2M tests • Commence exosome diagnostic development for Alzheimer’s Disease • Commence EXO-OC test clinical validation for ovarian cancer screening • Exosome therapeutic in vivo data • First sales of SubB2M breast cancer monitoring test • SubB2M ovarian cancer clinical validation study data • SubB2M breast cancer in-clinic monitoring study data Exosome program SubB2M program
RkJQdWJsaXNoZXIy MjE2NDg3